AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)

Idiopathic Recurrent Pericarditis Clinical Trial

— AIR TRIP  

Official title:

AnakInRa for Treatment of Recurrent Idiopathic Pericarditis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02219828
• Other study ID #: 40/08/13
• Secondary ID: 2013-001849-13
• Status: Completed
• Phase: Phase 4
• First received: August 14, 2014
• Last updated: December 17, 2015
• Start date: June 2014
• Est. completion date: October 2015

Study information

• Verified date: December 2015
• Source: Maria Vittoria Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Recent findings suggest that recurrent pericarditis (RP) may be a previously unrecognized autoinflammatory disease. The pivotal pathogenic role of interleukin (IL)-1 in RP has been shown by the achievement of complete responses after treatment with the recombinant IL-1-receptor antagonist, anakinra. Anakinra is the recombinant form of IL-1Ra. The proposed study is designed to demonstarate the efficacy of anakinra in RP.

Description:

This is a 8-month, multicenter (3 Italian centers), randomized, double-blind, placebo-controlled, multicenter, medication-withdrawal study to evaluate the efficacy, tolerability, and safety of anakinra in adults and children with idiopathic recurrent pericarditis (RP).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: October 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 5 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Patient's written informed consent for = 18 years of age before any assessment is performed. Parents' or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for patients < 18 years of age.

2. Age > 2 years and <70 years at screening visit;

3. Recurrent pericarditis defined as a first episode of acute pericarditis followed by recurrences (Ann Intern Med. 2011;155:409-14) (at least two recurrences for this study). First episode of pericarditis is diagnosed when at least two of the following criteria were present: pericarditic typical chest pain (sharp and pleuritic, improved by sitting up and leaning forward), pericardial friction rubs, widespread ST segment elevation or PR depressions not previously reported, and new or worsening pericardial effusion. Recurrence is diagnosed when chest pain recurs and one or more of the following signs is present: fever, pericardial friction rub, ECG changes, echocardiographic evidence of new or worsening pericardial effusion, and elevations in the white blood cell count, erythrocyte sedimentation rate or C-reactive protein. To be enrolled in this study, elevation of C-reactive protein is mandatory both in the first attack and in the following recurrences. We differentiate recurrences from incessant pericarditis, term used to define patients with continued activity of pericarditis (with a symptom-free interval of < 6 weeks) (Soler-Soler J, Sagristà-Sauleda J, Permanyer-Miralda G. Relapsing pericarditis. Heart. 2004;90:1364-8).

4. Specific etiologies excluded, including tuberculous, neoplastic or purulent etiologies, post-cardiac injury syndromes, and rheumatic autoimmune diseases.

5. Records to document the number of prior pericardial recurrences, the time interval between them as well as prior treatments must be made available from the medical charts.

6. Troponin values during at least one previous attack is recorded.

7. QuantiFERON (QFT-TB G In-Tube) test or positive Purified Protein Derivative (PPD) test has been previously made and recorded.

8. Patients will be enrolled at the time of a recurrent episode (at least the second recurrence, i.e. third episode) or "relapse" of pericarditis documented by the following criteria:

• recurrent pericardial pain (with a score of least 5 on the 21 circles VAS) AND

• increase in CRP=1 mg/dL (being normal value = 0 - 0.5 mg/dL ), AND

• one or more of the following signs: fever (= 37°C), pericardial friction rub, pertinent ECG changes, echocardiographic evidence of of new or worsening pericardial effusion (see definition above)

9. Continuous treatment with CS, the dose of which must not have been increased in the three days preceding enrolment

10. Women of child bearing potentials (WCBP), defined as pre-menarche females aged 8 years and above or all women physiologically capable of becoming pregnant, sexually active, must use an effective form of contraception. Medically approved contraception (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices) could include total abstinence. Reliable contraception should be maintained throughout the study and for 3 months after anakinra discontinuation. Women are considered post-menopausal and not WCBP if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. appropriate age, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks prior to study entry. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment she considered a WCBP.

Exclusion Criteria:

• Patients fulfilling any of the following criteria are not eligible for enrollment in this study:

1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL).

2. History of being immunocompromised, including a positive HIV at screening (ELISA and Western blot) test result.

3. Positive QuantiFERON (QFT-TB G In-Tube) test or positive Purified Protein Derivative (PPD) test (= 5 mm induration) performed after the first attack of pericarditis. Patients with a positive PPD test (= 5 mm induration) at screening may be enrolled only if they have either a negative chest X-ray or a negative QuantiFERON test.

4. Live vaccinations within three months prior to the start of the trial, during the trial, and up to three months following the last anakinra dose.

5. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases

6. History of significant other medical conditions, which in the Investigator's opinion would exclude the patient from participating in this trial including current pericarditis due to known diseases (e.g. tuberculosis, neoplastic or purulent causes, connective tissue diseases, acute rheumatic fever, etc.)

7. History of recurrent and/or evidence of active bacterial, fungal, or viral infection(s).

8. History of Type I hypersensitivity to anakinra.

9. History of poor compliance.

10. Use of any investigational drug (or biologic), or device within five half-lives of the drug prior to study entry or during the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Idiopathic Recurrent Pericarditis
• Pericarditis

Intervention

Drug:
• Anakinra
2mg/Kg daily sc up to 100mgday as maximum dose
• Placebo
Placebo

Locations

Country	Name	City	State
Italy	Internal Medicine Division, OSpedale Papa Giovanni XXIII	Bergamo
Italy	Pediatric Dept. Ospedale Gaslini	Genova
Italy	Cardiology Dpt, Maria Vittoria Hospital	Torino

Sponsors (1)

Lead Sponsor	Collaborator
Massimo Imazio

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence rate	Time to flare in the anakinra and placebo arms	8 months	No
Secondary	1. responder status in the open label phase	To assess the responder status in the open label phase at Day 8 and 60 and at the end of the study with the following three criteria all to be met: no or mild pericardial pain (a score =2.5 on a 21 circle VAS), AND; normal CRP levels (CRP =0.5 mg/dL), AND; absent or mild (=10 mm) echocardiographic effusion. Assessments will be performed at Days 4, and 8 (study Period 1), and then at Day 30, and Months 2, 4, 6, and 8 if not otherwise specified.	60 days	No
Secondary	2. change over time of the 3 outcome criteria, i.e. pericardial pain, CRP levels, and echocardiographic effusion;	Assessments will be performed at Days 4, and 8 (study Period 1), and then at Day 30, and Months 2, 4, 6, and 8 if not otherwise specified.	8 months	No
Secondary	3. time to response in the open label phase	Assessments will be performed at Days 4, and 8 (study Period 1), and then at Day 30, and Months 2, 4, 6, and 8 if not otherwise specified.	8 months	No
Secondary	4. percentage of patients who relapse in the withdrawal part in the two arms;	Assessments will be performed at Days 4, and 8 (study Period 1), and then at Day 30, and Months 2, 4, 6, and 8 if not otherwise specified.	8 months	No
Secondary	5. change over time in patient's/parent's global assessment of overall well being on a 21 circle VAS;	Assessments will be performed at Days 4, and 8 (study Period 1), and then at Day 30, and Months 2, 4, 6, and 8 if not otherwise specified.	8 months	No
Secondary	6. change over time in the global evaluation of disease activity by physicians on a 21 circle VAS	Assessments will be performed at Days 4, and 8 (study Period 1), and then at Day 30, and Months 2, 4, 6, and 8 if not otherwise specified.	8 months	Yes
Secondary	8. percentage off CS and any other concurrent medication at 6weeks	Assessments will be performed at Days 4, and 8 (study Period 1), and then at Day 30, and Months 2, 4, 6, and 8 if not otherwise specified.	6 weeks	No
Secondary	9. tolerability and safety of the treatment	To assess the tolerability and safety of the treatment, i.e. monitoring and recording all adverse events (AEs), with attention to local tolerability to s.c. injection, and serious adverse events (SAEs), and the regularly scheduled monitoring of hematology, blood chemistry, physical examinations, and vital signs including blood pressure over 8 months. Assessments will be performed at Days 4, and 8 (study Period 1), and then at Day 30, and Months 2, 4, 6, and 8 if not otherwise specified.	8 months	Yes